HRP20161424T1 - Supstituirani 6-amino-nikotinamidi koji nose skupinu koja sadrži oh kao modulatori kcnq2/3 - Google Patents

Supstituirani 6-amino-nikotinamidi koji nose skupinu koja sadrži oh kao modulatori kcnq2/3 Download PDF

Info

Publication number
HRP20161424T1
HRP20161424T1 HRP20161424TT HRP20161424T HRP20161424T1 HR P20161424 T1 HRP20161424 T1 HR P20161424T1 HR P20161424T T HRP20161424T T HR P20161424TT HR P20161424 T HRP20161424 T HR P20161424T HR P20161424 T1 HRP20161424 T1 HR P20161424T1
Authority
HR
Croatia
Prior art keywords
aliphatic residue
residue
unsubstituted
polysubstituted
mono
Prior art date
Application number
HRP20161424TT
Other languages
English (en)
Croatian (hr)
Inventor
Simon Lucas
Sven KÜHNERT
Gregor Bahrenberg
Wolfgang Schröder
Achim Kless
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20161424T1 publication Critical patent/HRP20161424T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20161424TT 2012-04-18 2013-04-17 Supstituirani 6-amino-nikotinamidi koji nose skupinu koja sadrži oh kao modulatori kcnq2/3 HRP20161424T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18
PCT/EP2013/001134 WO2013156154A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
EP13719386.8A EP2888233B1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
HRP20161424T1 true HRP20161424T1 (hr) 2016-12-16

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161424TT HRP20161424T1 (hr) 2012-04-18 2013-04-17 Supstituirani 6-amino-nikotinamidi koji nose skupinu koja sadrži oh kao modulatori kcnq2/3

Country Status (21)

Country Link
EP (1) EP2888233B1 (OSRAM)
JP (1) JP6033403B2 (OSRAM)
CN (1) CN104428287A (OSRAM)
AR (1) AR090739A1 (OSRAM)
AU (1) AU2013248637A1 (OSRAM)
BR (1) BR112014025840A2 (OSRAM)
CA (1) CA2870573A1 (OSRAM)
CY (1) CY1118255T1 (OSRAM)
DK (1) DK2888233T3 (OSRAM)
EA (1) EA201401142A1 (OSRAM)
ES (1) ES2605947T3 (OSRAM)
HK (1) HK1210173A1 (OSRAM)
HR (1) HRP20161424T1 (OSRAM)
HU (1) HUE030859T2 (OSRAM)
IL (1) IL235030A0 (OSRAM)
LT (1) LT2888233T (OSRAM)
MX (1) MX2014012494A (OSRAM)
PT (1) PT2888233T (OSRAM)
RS (1) RS55466B1 (OSRAM)
SI (1) SI2888233T1 (OSRAM)
WO (1) WO2013156154A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071654A2 (pt) * 2016-04-22 2019-02-19 Ono Pharmaceutical Co., Ltd. polimorfismo de cristal do ativador de canais kcnq2-5
JP7262468B2 (ja) * 2017-12-29 2023-04-21 スリーエム イノベイティブ プロパティズ カンパニー 熱硬化性2剤型加工用接着剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
DK2350093T3 (da) 2008-10-24 2012-11-12 Gruenenthal Gmbh Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
US8552200B2 (en) * 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators

Also Published As

Publication number Publication date
JP6033403B2 (ja) 2016-11-30
SI2888233T1 (sl) 2016-12-30
PT2888233T (pt) 2017-01-04
EP2888233A1 (en) 2015-07-01
EP2888233B1 (en) 2016-09-28
CY1118255T1 (el) 2017-06-28
WO2013156154A1 (en) 2013-10-24
ES2605947T3 (es) 2017-03-17
MX2014012494A (es) 2015-01-15
AU2013248637A1 (en) 2014-12-04
EA201401142A1 (ru) 2015-03-31
AR090739A1 (es) 2014-12-03
CA2870573A1 (en) 2013-10-24
JP2015514728A (ja) 2015-05-21
DK2888233T3 (en) 2017-01-09
HUE030859T2 (en) 2017-06-28
LT2888233T (lt) 2017-01-10
IL235030A0 (en) 2014-12-31
CN104428287A (zh) 2015-03-18
HK1210173A1 (en) 2016-04-15
BR112014025840A2 (pt) 2017-07-18
RS55466B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
IN2015DN01830A (OSRAM)
NZ594928A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
NZ593030A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
NZ610689A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
FI2291080T5 (fi) Uusia sfingosiinifosfaattireseptorimodulaattoreita
RU2015143906A (ru) Замещенные триазолопиридины и способы их применения
RU2015115064A (ru) Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
NZ596585A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
PH12021550674A1 (en) Protein tyrosine phosphatase inhibitors
HRP20150526T1 (hr) Supstituirani 2-oksi-kinolin-3-karboksamidi kao modulatori kcnq2/3
MX336505B (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
MX2013010171A (es) Antagonistas del receptor de interleucina-1.
RU2011147201A (ru) Регероматические и ароматические пиперазинил ацетидинил амиды как моноцилглицероловые ингибиторы липазы
EP2526099A4 (en) IMPROVED METHOD FOR THE MANUFACTURE OF AMID INTERMEDIATE PRODUCTS AND ITS APPLICATION
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
IN2012DN02502A (OSRAM)
MX2012008413A (es) Composicion novedosa de retigabina.
IN2013DN02555A (OSRAM)
HRP20100113T1 (hr) Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
EP4470611A3 (en) Levodopa and carbidopa intestinal gel and methods of use
HRP20150520T1 (hr) Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3
RU2590977C2 (ru) Производные n-ациламинокислот для лечения таких патологий кожи, как целлюлит
RS55466B1 (sr) Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3